Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday. Laboratory Corp reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78. Sales increased 6.2% year-over-year to $3.22 billion, beating the consensus of $3.19 billion. Diagnostics Laboratories revenue for the quarter was $2.52 billion, an increase of 7.9%. Biopharma Laboratory Services revenue increased 1. ...

PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw BURLINGTON, N.C., Aug. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for PGDx elio™ plasma focus Dx – the industry's first and only kitted, pan-solid tumor liqu ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.94 in the second quarter of 2024, up 15.2% from the year-ago quarter's figure. The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line also beat the Zacks Consensus Estimate by 4.2%. On a GAAP basis, EPS in the second quarter was $2.43, up 14.6% from last year's comparable period. Revenues Revenues in the quarter under review ...

Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78. Sales increased 6.2% year-over-year to $3.22 billion, beating the consensus of $3.19 billion. The increase was due to organic revenue of 3.8%, acquisitions, and net of divestitures of 2.5%, partially offset by foreign currency translation of (0.1%). The 3.8% increase in organic revenue was driven by a 4.5% increase in the company's organic Base Business, partially offset ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.94 in the second quarter of 2024, up 15.2% from the year-ago quarter's figure. The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line also beat the Zacks Consensus Estimate by 4.2%. On a GAAP basis, EPS in the second quarter was $2.43, up 14.6% from last year's comparable period. Revenues Revenues in the quarter under review ...

For the quarter ended June 2024, Labcorp (LH) reported revenue of $3.22 billion, up 6.2% over the same period last year. EPS came in at $3.94, compared to $3.42 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.2 billion, representing a surprise of +0.78%. The company delivered an EPS surprise of +4.23%, with the consensus EPS estimate being $3.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...

Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 4.23%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $3.46 per share when it actually produced earnings of $3.68, delivering a surprise of 6.36%. Over the last four quarters, the ...

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash us ...

BURLINGTON, N.C., and FREMONT, Calif., July 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers. Labcorp recently introduced Labcorp® Plasma Detect™, the first ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is slated to report second-quarter 2024 results on Aug 1 before market open. The Zacks Consensus Estimate for Labcorp's second-quarter 2024 revenues is pegged at $3.20 billion. This suggests a 5.4% rise from the year-ago reported figure. Estimates for Labcorp's Q2 earnings have remained unchanged at $3.78 per share in the past 30 days. In the second quarter of 2024, both Diagnostic Laboratories (Dx) and Biopharma Laboratory Services ("BLS") segme ...